Table 1.
Clinical information, cardiac magnetic resonance imaging, and quantitative echocardiographic data from all athletes included in this study.
| Clinical parameter | Mean (SD) | Mean (SD) | p |
|---|---|---|---|
| COVID-19 | Non-COVID-19 | ||
| N | 8 | 4 | |
| Age,y | 27 (3.5) | 22 (2.6) | |
| Weight, kg | 96.7 (5.4) | 96.0 (8.0) | ns |
| Height, cm | 190.8 (5.4) | 193.5 (10.4) | ns |
| Time from the positive COVID-19 test result to clinical tests, d | 19 (7) | ||
| Clinical symptoms | Yes | No | |
| No symptoms, No | 1 | ||
| Headache, No | 5 | ||
| Rhinitis, No | 4 | ||
| No sense of taste and/or smell, No | 3 | ||
| Chest pain, No | 2 | ||
| Breathing problems, No | 2 | ||
| Sore throat, cough, sniffles, No | 1 | ||
| Listlessness, No | 1 | ||
| Aching limbs, No | 1 | ||
| ECG-abnormalities rest, No | 0 | 0 | |
| ECG-abnormalities exercise, No | 1 | 0 | |
| Echocardiographic measurements | |||
| Global longitudinal strain (GLS), % | − 18.1 (1.8) | − 17.4 (1.7) | ns |
| Pericardial effusion, No | 1 | 0 | |
| Cardiac MRI measurements (left ventricular) | |||
| Ejection fraction, % | 58.3 (4.7) | 58.3 (4.1) | ns |
| End-diastolic volume index, ml/m2 | 60.9 (4.8) | 61.1 (6.0) | ns |
| End-systolic volume index, ml/m2 | 25.6 (4.1) | 25.5 (3.0) | ns |
| Stroke volume index, ml/m2 | 35.4 (3.2) | 35.6 (4.6) | ns |
| Native T1 value, ms (reference: 1250 ms) | 1205 (55) | 1215 (24) | ns |
| Base | 1202 (53) | 1216 (41) | ns |
| Middle | 1203 (61) | 1205 (27) | ns |
| Apex | 1210 (54 | 1222 (11) | ns |
| Number of segments above reference | 2.6 (3.5) | 2.5 (3.7) | ns |
| Native T2 value, ms (reference: 45 ms) | 49.1 (4.4) | 48.7 (0.8) | ns |
| Base | 47.8 (4.0) | 48.2 (2.8) | ns |
| Middle | 48.5 (3.5) | 49.4 (1.1) | ns |
| Apex | 51.2 (4.4) | 48.7 (2.0) | ns |
| Number of segments above reference | 13.6 (3.5) | 13.3 (4.0) | ns |
| Late gadolinium enhancement present, No | 2 | 0 | |
ECG Electrocardiogram, ns Not significant, No Number.